Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s diseaseViviane Tabar, Claire Henchcliffe, W. Stemple et al.|Nature|2025Cited by 131
510 Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: Results From a Phase 1 Study of BemdaneprocelViviane Tabar, Antoine Lampron, Kenny Yu et al.|Neurosurgery|2024Cited by 3
Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.001)Harini Sarva, Viviane Tabar, Claire Henchcliffe et al.|Neurology|2024Cited by 0
Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.007)Claire Henchcliffe, Viviane Tabar, Harini Sarva et al.|Neurology|2024Cited by 0
Imaging Outcomes of a Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: 18-month Results from a Phase 1 Study of Bemdaneprocel (S30.005)Claire Henchcliffe, David Eidelberg, Yilong Ma et al.|Neurology|2024Cited by 0